NTLA-2001
Intellia Therapeutics
['cardio', 'cardiomyopathy', 'crispr']
a novel crispr-based in vivo gene editing therapy reduced transthyretin levels in patients with hereditary transthyretin amyloidosis with cardiomyopathy #aha22 #cardiotwitter 
The content you need, when you need it.